NDRG2在人甲状腺肿瘤中的表达及其对甲状腺癌细胞增殖和侵袭的影响
|
摘要
甲状腺肿瘤是临床上的常见病和多发病。虽然甲状腺恶性肿瘤占人类所有癌的1%左右,但仍是内分泌系统最常见的恶性病变,严重威胁着人类的生命健康。除乳头状甲状腺癌经包括手术切除、内分泌治疗及放射性核素治疗在内的临床综合治疗后,可望获得较好的预后外,其他病理类型的甲状腺恶性肿瘤,预后仍然较差。而继续对甲状腺肿瘤进行深入研究,进一步取得对甲状腺恶性肿瘤发生、发展的分子机制的更深入的认识,包括寻找与其密切相关的新基因,仍显得十分必要。
人NDRG2是我校生物化学与分子生物学教研室首先克隆并报道的一个新基因。对其进行深入研究结果表明,其在多种正常组织均有表达,而在结肠癌、胶质瘤、白血病、淋巴瘤和腮腺癌等10余种肿瘤组织或细胞系中无表达或低表达,是多种肿瘤及相应正常组织细胞的差异表达基因,因此推测该基因可能和肿瘤的发生、发展有关,被列为一新的抑癌候选基因。并且最近的研究结果证实,NDRG2的表达是受到Myc的调控。
NDRG2与人甲状腺肿瘤的关系先前并无明确报道。NDRG2在人甲状腺肿瘤中有无表达及其表达模式如何,是首先需要明确的问题。本实验的第一部分就围绕着这一问题进行展开。我们首先运用组织芯片技术对NDRG2在人甲状腺肿瘤中的表达进行了免疫组织化学染色检测,结果发现,NDRG2在正常甲状腺组织中呈高表达,在甲状腺腺瘤组织中呈弱表达或中等强度表达,而在多种病理类型的甲状腺癌组织中呈不表达或极低表达。其次通过收集临床标本进行免疫组织化学染色和western印迹检测,得到了相似结果,这就说明NDRG2在蛋白表达水平上呈差异性表达。此发现也鼓励我们进一步对NDRG2在甲状腺肿瘤中的RNA表达水平进行了检测,通过RT-PCR、real-time PCR方法对收集来的临床肿瘤标本的检测,结果和上述实验结果一致。从而证明NDRG2在正常甲状腺组织及甲状腺癌组织中是一明显差异性表达性基因。
为进一步了解NDRG2在甲状腺肿瘤发生、发展中所起的作用。我们运用NDRG2的过表达腺病毒载体,感染甲状腺滤泡状癌细胞株FTC-133从而实现NDRG2的过表达,通过RT-PCR和Western-blot检测感染成功后,对甲状腺癌细胞株进行了MTT、平板克隆形成检测及细胞周期测定,结果表明,过表达NDRG2可以明显抑制甲状腺癌细胞株的增殖。通过Trans-well和细胞划痕实验检测,结果显示,过表达NDRG2可以明显抑制甲状腺癌细胞株的侵袭能力。
我们的实验结果证明了NDRG2在正常甲状腺组织及甲状腺癌组织中是一差异性表达性基因,过表达的NDRG2对甲状腺癌细胞株的增殖、侵袭能力呈现明显的抑制作用。由此推断,NDRG2可能参与了甲状腺肿瘤的发生、发展。丰富了对NDRG2和甲状腺肿瘤的认识,从而为以后对甲状腺肿瘤的深入研究奠定了实验基础。
Thyroid cancer is one of the common and frequent encountered diseases. Although the occurrence of thyroid cancer constitutes only about 1%of the total human cancers,it is the most common malignant disease in endocrine system and threats human health seriously.Except for the relative better prognosis of the surgical operation,the combined treatment including endocrine hormone and radioactive isotope therapy to papillary thyroid carcinoma,the prognosis of other pathological types is still bad.So,it is very impending to deeply investigate the carcinogenesis mechanism of thyroid tumor.And the discovery and functional research of the thyroid cancer related genes are very intriguing.
Human NDRG2(N-Myc downstream-regulated gene) is the novel gene cloned by the department of biochemsitry and molecular chemistry of our university.The primary research work about NDRG2 shows that Ndrg2 expresses ubiquitously in almost all normal tissues.However,it expresses very low or undetectable in nearly 10 tumor tissues or cell lines including colon cancers, glioma,leukemia,lymphoma and parotid cancers etc.It is presumptive that human NDRG2 is close to tumor progression and we believe NDRG2 is one novel candidate of tumor supressor gene.Especially,it is confirmed that NDRG2 is one of the downstream regulated target gene of Myc,the famous oncogene.
Untill now,there isn't the research report about NDRG2 with thyroid cancer. So,firstly,we should elucidate the expression profiling of human NDRG2 in thyroid tumors.The first part of our work to answer this question.The preliminary detection of Ndrg2 expression in thyroid tumor is examined using the tissue microarray.With the immunostainning analysis,the conspicuous different expression pattern of Ndrg2 was detected between thyroid carcinoma and the normal tissues.We find that Ndrg2 expresses very abundant in the normal thyroid and lower or undetectable in much types of thyroid cancers statistically significant.Further,we get the similar results by immunochemistry and western blotting analysis in the collected thyroid cancer samples.Our results demonstrate that the protein level of Ndrg2 differentiate between the nornal and tumor thyroid tissues.Based on the detection of Ndrg2 protein expression in thyroid cancer tissues,real-time PCR was used to investigate NDRG2 mRNA level in thyroid tissue with carcinoma.Expectably,the expression of NDRG2 mRNA in thyroid cancer tissues is relatively low than the normal group,which is accordant with the protein level.Thus,we believe that human NDRG2 is the differentiated expression gene between normal thyroid tissues and tumors.
To further explore the potential function of human NDRG2 during the progression of thyroid cancer,we overexpress NDRG2 in papillary thyroid cancer cells FTC-13 3 by the infection of NDRG2 adenovirus.RT-PCR and Western-blot methods are used to confirm the expression status MTT,flat clone formation and cell cycle analysis demonstrate that overexpression of NDRG2 could inhibit the proliferation of thyroid cancer cells significantly.Trans-well and scratch test show that NDRG2 overexpression also causes the decrease of cell metastasis ablity.
Our present results demonstrate that NDRG2 is the differentiated expression gene between normal thyroid tissues and tumors.The overexpression of human NDRG2 can suppress the proliferation and metastasis of thyroid cancer cells.It is presumable that NDRG2 participates the carcinogenesis and development of thyroid tumor.The data enriches the work of human NDRG2 with thyroid cancer and lay the foundation for the research of thyroid tumor.
人NDRG2是我校生物化学与分子生物学教研室首先克隆并报道的一个新基因。对其进行深入研究结果表明,其在多种正常组织均有表达,而在结肠癌、胶质瘤、白血病、淋巴瘤和腮腺癌等10余种肿瘤组织或细胞系中无表达或低表达,是多种肿瘤及相应正常组织细胞的差异表达基因,因此推测该基因可能和肿瘤的发生、发展有关,被列为一新的抑癌候选基因。并且最近的研究结果证实,NDRG2的表达是受到Myc的调控。
NDRG2与人甲状腺肿瘤的关系先前并无明确报道。NDRG2在人甲状腺肿瘤中有无表达及其表达模式如何,是首先需要明确的问题。本实验的第一部分就围绕着这一问题进行展开。我们首先运用组织芯片技术对NDRG2在人甲状腺肿瘤中的表达进行了免疫组织化学染色检测,结果发现,NDRG2在正常甲状腺组织中呈高表达,在甲状腺腺瘤组织中呈弱表达或中等强度表达,而在多种病理类型的甲状腺癌组织中呈不表达或极低表达。其次通过收集临床标本进行免疫组织化学染色和western印迹检测,得到了相似结果,这就说明NDRG2在蛋白表达水平上呈差异性表达。此发现也鼓励我们进一步对NDRG2在甲状腺肿瘤中的RNA表达水平进行了检测,通过RT-PCR、real-time PCR方法对收集来的临床肿瘤标本的检测,结果和上述实验结果一致。从而证明NDRG2在正常甲状腺组织及甲状腺癌组织中是一明显差异性表达性基因。
为进一步了解NDRG2在甲状腺肿瘤发生、发展中所起的作用。我们运用NDRG2的过表达腺病毒载体,感染甲状腺滤泡状癌细胞株FTC-133从而实现NDRG2的过表达,通过RT-PCR和Western-blot检测感染成功后,对甲状腺癌细胞株进行了MTT、平板克隆形成检测及细胞周期测定,结果表明,过表达NDRG2可以明显抑制甲状腺癌细胞株的增殖。通过Trans-well和细胞划痕实验检测,结果显示,过表达NDRG2可以明显抑制甲状腺癌细胞株的侵袭能力。
我们的实验结果证明了NDRG2在正常甲状腺组织及甲状腺癌组织中是一差异性表达性基因,过表达的NDRG2对甲状腺癌细胞株的增殖、侵袭能力呈现明显的抑制作用。由此推断,NDRG2可能参与了甲状腺肿瘤的发生、发展。丰富了对NDRG2和甲状腺肿瘤的认识,从而为以后对甲状腺肿瘤的深入研究奠定了实验基础。
Thyroid cancer is one of the common and frequent encountered diseases. Although the occurrence of thyroid cancer constitutes only about 1%of the total human cancers,it is the most common malignant disease in endocrine system and threats human health seriously.Except for the relative better prognosis of the surgical operation,the combined treatment including endocrine hormone and radioactive isotope therapy to papillary thyroid carcinoma,the prognosis of other pathological types is still bad.So,it is very impending to deeply investigate the carcinogenesis mechanism of thyroid tumor.And the discovery and functional research of the thyroid cancer related genes are very intriguing.
Human NDRG2(N-Myc downstream-regulated gene) is the novel gene cloned by the department of biochemsitry and molecular chemistry of our university.The primary research work about NDRG2 shows that Ndrg2 expresses ubiquitously in almost all normal tissues.However,it expresses very low or undetectable in nearly 10 tumor tissues or cell lines including colon cancers, glioma,leukemia,lymphoma and parotid cancers etc.It is presumptive that human NDRG2 is close to tumor progression and we believe NDRG2 is one novel candidate of tumor supressor gene.Especially,it is confirmed that NDRG2 is one of the downstream regulated target gene of Myc,the famous oncogene.
Untill now,there isn't the research report about NDRG2 with thyroid cancer. So,firstly,we should elucidate the expression profiling of human NDRG2 in thyroid tumors.The first part of our work to answer this question.The preliminary detection of Ndrg2 expression in thyroid tumor is examined using the tissue microarray.With the immunostainning analysis,the conspicuous different expression pattern of Ndrg2 was detected between thyroid carcinoma and the normal tissues.We find that Ndrg2 expresses very abundant in the normal thyroid and lower or undetectable in much types of thyroid cancers statistically significant.Further,we get the similar results by immunochemistry and western blotting analysis in the collected thyroid cancer samples.Our results demonstrate that the protein level of Ndrg2 differentiate between the nornal and tumor thyroid tissues.Based on the detection of Ndrg2 protein expression in thyroid cancer tissues,real-time PCR was used to investigate NDRG2 mRNA level in thyroid tissue with carcinoma.Expectably,the expression of NDRG2 mRNA in thyroid cancer tissues is relatively low than the normal group,which is accordant with the protein level.Thus,we believe that human NDRG2 is the differentiated expression gene between normal thyroid tissues and tumors.
To further explore the potential function of human NDRG2 during the progression of thyroid cancer,we overexpress NDRG2 in papillary thyroid cancer cells FTC-13 3 by the infection of NDRG2 adenovirus.RT-PCR and Western-blot methods are used to confirm the expression status MTT,flat clone formation and cell cycle analysis demonstrate that overexpression of NDRG2 could inhibit the proliferation of thyroid cancer cells significantly.Trans-well and scratch test show that NDRG2 overexpression also causes the decrease of cell metastasis ablity.
Our present results demonstrate that NDRG2 is the differentiated expression gene between normal thyroid tissues and tumors.The overexpression of human NDRG2 can suppress the proliferation and metastasis of thyroid cancer cells.It is presumable that NDRG2 participates the carcinogenesis and development of thyroid tumor.The data enriches the work of human NDRG2 with thyroid cancer and lay the foundation for the research of thyroid tumor.
引文
[1] Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003, 53: 5-26.
[2] Hundahl S A, Fleming ID, Fremgen AM, Menck HR. A National Cancer Date Base reort on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 1998, 83: 2638-2648.
[3] Ain,K.B. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaces. Thyroid, 1998, 8: 715-726.
[4] Stewart BW, Kleihues P. World Cancer Report, 2003, IARC Press: Lyon.
[5] Randolph GW. Follicular carcinoma of the thyroid. 2003, Saunders: Philadelphia.
[6] Negri E, Dal Maso L, Ron E, Lavecchia C, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F, Wingren G, Rosaria Galani M, Hardell L, Glattre E, Lund E, Levi F, Linos D, Braga C, Franceschi S. A pooled analysis of case-control studies of thyroid cancer. Ⅱ .Menstrual and reproductive factors. Cancer Causes Control, 1999, 10: 143-155.
[7] Tai P, Mould RF, Prysyazhnyuk Aye, Gristchenko VG, Obodovsky IA. Descriptive epidemiology of thyroid caicinoma. Current Oncology, 2003, 10: 54-65.
[8] Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer, 2002, 2: 543-549.
[9] Williams ED, Doniach I, Bjarnason O, MichieW. Thyriod cancer in an iodide rich area: a histopathological study. Cancer, 1977, 39: 215-222.
[10] Cooper DS, Axelrod L, DeGroot LJ, Vickery ALJr, Maloof F. Congenital goiter and the development of metastatic follicular carcinoma with evidence for a leak of nonhormonal iodide: clinical, pathological, kinetic, and biochemical studies and a review of the literature. J Clin Endocrinol Metab, 1981, 52: 294-306.
[11] Ruben Harach H. Familial nonmedullary thyroid neoplasia. Endocr Pathol, 2001, 12:97-112.
[12] Harach HR, Escalante DA, Day ES.Thyroid cancer and thyroiditis in salta, Argentina: a 40-yr study in relation to iodine prophylaxis.Endocr Pathol, 2002, 13: 175-181.
[13] Tamimi DM. The association between chronic lymphocytic thyrioditis and thyroid tumors. Int J Surg Pathol, 2002, 10: 141-146.
[14] Takahashi MH, Thomas GA, Williams ED. Evidence for mutual interdependence of epithelium and stromal lymphoid cells in a subset of papillary carcinomas. Br J Cancer, 1995, 72: 813-817.
[15] Schaffler A, Palitzsch KD, Seiffarth C, Riedhammer FJ Hofstaedter F. Coexisting thyroiditis is associatd with lower tumor stage in thyroid carcinoma. Eur J Clin Invest, 1998,28: 838-844.
[16] Toti P, Tanganelli P, Schurfelld K, Stumpo M, Barbagli L, Luzi P. Scarring in papillary carcinoma of the thyroid: report of two new cases with exuberant nodular fasciitis-He stroma. Histopathology, 1999, 35: 418-422.
[17] Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer, 2003, 103: 105-109.
[18] Kuratomi Y, Kumamoto Y, Sakai Y, Komiyama S. Carotid body tumor associated with differentiated thyroid carcinoma. Eur Arch Otorhinolaryngol 251 Suppl, 1994, 1: S91-S94.
[19] Gardner EJ. A genetic and clinical study of intertinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet, 1991, 167-176.
[20] Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet: 1953, 5: 139-148.
[21] Houlston RS. Genetic predisposition to non-medullary thyroid cancer. Nucl Med Commun, 1998, 19: 911-913.
[22] Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. Mod Pathol , 1999, 12:400-411.
[23] Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S. Germline mutation of the APC gene in paytients with familial adenomatous polyposisi-associated thyroid carcinoma: result from a uropean cooperative study. J Clin Endocrinol Metab, 2000, 85: 286-292.
[24] Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. PTEN is essential for embryonic development and tumor suppression. Nat Genet , 1998, 19: 348-355.
[25] Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res , 2003, 63: 1454-1457.
[26] Soares P, Trovisco V, Rocha AS,Lima J, Castro P, Preto A, Maximo V,Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC tearrangements are ailernative events in the etiopathogenesis of papillary thyroid carcinoma. Oncogene, 2003, 22: 4578-4580.
[27] Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE. Ras point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab, 2003, 88: 2318-2326.
[28] Pisarchik AV, Ermak G, Fomicheva V, Kartel NA, Figge J. The ret/ PTC 1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. Thyroid, 1998, 8: 133-139.
[29] Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by RET/ PTC 1 oncogene in thyroid-targeted transgenic mice. Oncogene , 1999, 18: 3659-3665.
[30] Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D. Papillary thyroid carcinoma oncogene(RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol, 1998, 153: 1443-1450.
[31] Nikiforova MN, Kimnra ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. BRAF mutation in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 2003, 88: 5399-5404.
[32] Oyama T, Ichimura E, Sano T. C-met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Int, 1998, 48:763-768.
[33] Ruco LP, Ranalli T, Marzullo A, Biano P, Prat M, Comoglio PM, Baroni CD. Expression of Met protein in thyroid tumors. J Pathol, 1996, 180: 266-270.
[34] Komoike Y, Tamaki Y, Sakita I. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma. Int J Oncol, 1999, 14: 1157-1162.
[35] Schulte KM, Staudt S, Niederracher D. Rare loss of heterozygosity of the MTS 1 and MTS 2 tumor suppressor genes in differentiated human thyroid cancer. Horm Metab Res, 1998, 30: 549-554.
[36] Yamashita H, Noduchi S. Thyroid cancer associated with adenomatous goiter: An analysis of the incidence and clinical factors. Jap J Surg , 1997, 27: 495-499.
[37] Grunwald F, Kaelicke T. Fluorine-fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study. Eur J Nucl Med, 1999,26: 1547-1552.
[38] Bennedbaek FN, Hegedus L. Management of the solitary thyroid nodule: a retrospective analysis of eighty cases. Thyroid, 2000, 8: 1039-1044.
[39] Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med, 1993, 13: 699-709.
[40] Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky , Haugen BR, Sherman SL, Cooper DS, Braunstein GD, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for lowrisk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 2003, 88: 1433-1441.
[41] Elisei R, Bottici V, LuchettiF, Di Coscio G, Romei C, Grasso L. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab, 2004, 89: 163-168.
[42] Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature , 1996, 379: 458-460.
[43] Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM. Cloning of the human sodium iodide smporter. Biochem Biophys Res Commun , 1996, 226: 339-345.
[44] Schmutzler C, Winzer R, Meissner-Weigl. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun, 1997, 240: 832-838.
[45] Woolner LB, Lemmon ML, Beahrs OH, Black BM, McConahey WM, Keating FR. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J Clin Endocrinol Metab, 1960, 20:89-105.
[46] Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the U.S.,1985-1995. Cancer , 1998, 82: 2638-2648.
[47] Shaha AR. The National Cancer Date Base report on thyroid carcinoma.Reflections of practice patterns. Cancer, 1998, 83: 2434-2436.
[48] Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a populatin-based study of 15,698 cases for the Surveillance, Epidemiology and End Results(SEER) Program 1973-1991. Cancer , 1997, 79: 564-573.
[49] Ando H, Funahashi H, Ito M, Imai T, Takagi H. Proliferating cell nuclear antigen expression in papillary thyroid carcinoma. J Clin Pathol, 1996, 49: 657-659.
[50] Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. Downregulation of p27klpl and Ki67/Mibl labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol, 1999, 23: 678-685.
[51]Aust G,Eichler W,Laue S,Lehmann I,Heldin NE,Lotz O,Scherbaum WA,Dralle H,Hoang Vu C.Cd97:a differentiation marcker in human thyroid caicinomas.Cancer Res,1997,57:1798-1806.
[52]Walgenbach S,Sternheirn E,Bittinger F,Gorges R,Andreas J,Junginger T.Prognostic value of e-cadherin in papillary thyroid carcinoma.Chirurg,1998,69:186-190.
[53]Fontanini G,Vignati S,Pacini F,Pollina L,Basolo F.Microvessel count:an indicator of poor outcome in medullary thyroid caicinoma but not in other types of thyroid caicinoma.Mod Patho,1996,19:636-641.
[54]Wong NA,Willott J,Kendall MJ,Sheffield EA.Mesurement of vascularity as a diagnostic and prognostic tool for well differentiated thyroid tumors'comparison of different methods of assessing vascularity.J Clin Pathol,1999,52:593-597.
[55]邓艳春,药立波,刘新平,等.人脑内ACP样结构域新基因的发现.生物化学与生物物理进展,2001;28(1):72-76.
[56]Nagase T,Ishikawa K,Suyama M,Kikuno R,Hirosawa M,Miyajima N,Tanaka A,Kotani H,Nomura N,Ohara O,Prediction of the coding sequences of unidentified human genes.ⅩⅢ.The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro,DNA Res,1999;6(1):63-70.
[57]李剑,刘新平,林树新,等.一种新的抑癌候选基因—NDRG2在人类正常组织及相应肿瘤组织中的表达.生物化学与生物物理进展,2002;29(1):223-227.
[58]Qu X,Zhai Y,Wei H,Zhang C,Xing G,Yu Y,He F.Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family,Mol Cell Biochem,2002;229(1-2):35-44.
[59]王立峰.应激刺激对NDRG2蛋白在细胞内定位的影响.第四军医大学硕士论文,2003年P79-81.
[60]Jing Zhang,Junye Liu,Xia Li,Fuyang Li,Lifeng Wang,Jian Zhang,Xinping Liu,Lan Shen,Na Liu,Yanchun Deng,Angang Yang,Hua Han,Mujun Zhao,Libo Yao.The physical and functional interaction of NDRG2with MSP58 in cells.Biochemical and Biophysical Research Communications,2007;352:6-11.
[61]Kaelin WG Jr.Functions of the retinoblastoma protein,Bioessays.1999;21:950-958.
[62]Tong D,Kucera E,Schuster E,Schmutzler RK,Swoboda H,Reinthaller A,Leodolter S,Zeillinger R.Loss of heterozygosity(LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors,Int J Cancer,2000;88:319-322
[63]Manel Esteller,CpG island hypermethylation and tumor suppressor genes:a booming present,a brighter future,Oncogene,2002;21:5427-5440.
[64]Pamela M.Pollock,Mitchell S.Stark,Jane M.Palmer.Mutation Analysis of the CDKN2A Promoter in Australian Melanoma Families,Genes,Chromosomes & Cancer.2001,32:89-94.
[65]Deng Y,Yao L,Chau L,Ng SS,Peng Y,Liu X,Au WS,Wang J,Li F,Ji S,Han H,Nie X,Li Q,Kung HF,Leung SY,Lin MC,N-Myc downstream-regulated gene 2(NDRG2) inhibits glioblastoma cell proliferation,Int J Cancer,2003,106(3):342-347.
[66]刘娜,刘新平,王立峰,张健,王晓斌,药立波.抑癌侯选基因NDRG2在乳腺肿瘤组织及乳腺癌细胞系中的表达分析.第四军医大学学报,2004;25(12):1065-1068.
[67]Hu XL,Liu XP,Lin SX,Deng YC,Liu N,Li X,Yao LB.NDRG2 expression and mutation in human liver and pancreatic cancers, World J Gastroenterol, 2004, 10(23):3518-3521.
[68] Reetta (A|¨)ss(a|¨)m(a|¨)ki, Maarit Sarlomo-Rikala, Jose Antonio Lopez-Guerrero, Jerzy Lasota 3,Leif C. Andersson, Antonio Llombart-Bosch, Markku Miettinen, Sakari Knuutila .Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors, Genes Chromosomes Cancer, 2007, 46(6): 564-567.
[69] Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G,Gutmann DH, Perry A, Integrative genomic analysis identifies NDRG2 as a candidatetumor suppressor gene frequently inactivated in clinically aggressive meningioma, Cancer Res, 2005, 65: 7121-7126.
[70] Wu GQ, Liu XP, Wang LF, Zhang WH, Zhang J, Li KZ, Dou KF, Zhang XF, Yao LB. Induction of apoptosis of HepG2 cells by NDRG2, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2003, 19(4): 357-360.
[71] Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S, Yang A, Han H, Zhang Y, Zhang J, Han W, Liu X. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells.Cell Physiol Biochem. 2008, 21(1-3): 239-250.
[72] Hu XL, Liu XP, Deng YC, Lin SX, Wu L, Zhang J, Wang LF, Wang XB, Li X, Shen L, Zhang YQ, Yao LB. Expression analysis of the NDRG2 gene in mouse embryonic and adult tissues. Cell Tissue Res, 2006, 325(1): 67-76.
[73] Zhang J, Wang JC, Han YH, Wang LF, Ji SP, Liu SX, Liu XP, Yao LB. High expression of bcl-x(L) in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol, 2005, 113(4): 247-254.
[74] Jian Zhang, Fuyang Li, Xinping Liu, Lan Shen, Junye Liu, Jin Su, and Libo Yao. The repression of human differentiation related gene NDRG2 expression by MYC via MIZ 1 dependent interaction with the NDRG2 core promoter. J Biol Chem, 2006, 281(51) : 39159-39168.
[75] Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK, Chang YS, Paik SG,Lim JS. Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells, FEBS Lett, 2003; 553(3): 413-418.
[76] James T. Murray, David G. Campbell, Nicholas Morrice, Gillian C. Auld, Natalia Shpiro, Rodolpho Marquez, Mark Peggie, Jenny Bain, Graham B. Bloomberg, Florian Grahammer. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3 . Biochem, 2004, 384: 477-488.
[77] Lang F, Cohen P. Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. Science STKE, 2001, 108: 17.
[78] Firestone G.L, Giampaolo J.R, O'Keeffe B.A. Stimulus-dependent regulation of serum and glucocorticoid-induced protein kinase (SGK) transcription, sub-cellular location and enzymatic activity. Cell. Physiol. Biochem, 2003; 13: 1-12.
[79] Mitchelmore C, Buchmann-Moller S, Rask L, West MJ, Troncoso JC, Jensen NA. NDRG2: a novel Alzheimer's disease associated protein. Neurobiol Dis, 2004 ; 16(1): 48-58.
[80] Takahashi K, Yamada M, Ohata H, Momose K, Higuchi T, Honda K, Yamada M. Expression of Ndrg2 in the rat frontal cortex after antidepressant and electroconvulsive treatment. Int J Neuropsychopharmacol, 2005, 8(3): 381-389.
[81] Kou Takahashi, Misa Yamada, Hisayuki Ohata, Kazuo Hond, Mitsuhiko Yamad. Ndrg2 promotes neurite outgrowth of NGF-differentiated PC12 cells . Neuroscience Letters, 2005, 388 : 157-162.
[82] James G. Burchfield, Alecia J. Lennard, Sakura Narasimhan, William E. Hughes,Valerie C. Wasinger, Garry L. Corthals, Tomohiko Okuda, Hisato Kondoh,Trevor J. Biden, and Carsten Schmitz-Peiffer. Akt Mediates Insulin-stimulated Phosphorylation of Ndrg2. The Journal Of Biological Chemistry, 2004, 279(18) : 18623-18632.
[83] Sheerazed Boulkroun, Michel Fay, Maria-Christina Zennaro, Brigitte Escoubet, Frederic Jaisser, Marcel Blot-Chabaud, Nicolette Farman, Nathalie Courtois-Coutry. Characterization of Rat NDRG2 (N-Myc Downstream RegulatedGene 2), a Novel Early Mineralocorticoid-specific Induced Gene. The Journal Of Biological Chemistry, 2002, 277(35): 31506-31515.
[84] Sheerazed Boulkroun, Cathi Le Moellic,Marcel Blot-Chabaud, Nicolette Farman Nathalie Courtois-Coutry. Expression of androgen receptor and androgen regulation of NDRG2 in the rat renal collecting duct. Arch Eur J Physiol, 2005, 451: 388-394.
[85] Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis GRP78/BiP and novel genes. J Biol Chem, 1996, 271(47): 29659-65.
[86] van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in Colorectal neoplasms. Lab Invest, 1997, 77(1): 85-92.
[87] Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem, 2002, 229(1-2): 35-44. [88] Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics. 2001,73: 86-97.
[89] Lachat P, Shaw P, Gebhard S, Van Belzen N, Chaubert P, Bosman FT. Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol, 2002, 118(5): 399-408.
[90] Kalaydjieva L, Hallmayer J, Chandler D, Savov A, Nikolova A, Angelicheva D, King R. H, Ishpekova B. Gene mapping in Gypsies identifies a nove demyelinating neuropathy on chromosome 8q24. Nature Genet, 1996, 14: 214-217.
[91] van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in Colorectal neoplasms. Lab Invest, 1997, 77(1): 85-92.
[92] Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert P, Bosman FT. Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol, 2002, 118(5): 399-408.
[93] Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res, 1998; 58(19): 4439-4444.
[94] Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation related, putative metastatic suppressor gene in human colon cancer. Cancer Res, 2000, 60(3): 749-755.
[95] Plonczynski M, Hardy CL, Safaya S, Harrell A, McCoy L, Brinson A, Agwarangbo L, Steinberg MH. Induction of globin synthesis in K562 cells is associated with differential expression of transcription factor genes. Blood Cells Mol Dis, 1999,25(3-4): 156-165.
[96] Piquemal D, Joulia D, Balaguer P, Basset A, Marti J, Commes T. Differential expression of the RTP/Drgl/Ndrl gene product in Proliferating and growth arrested cells. Biochim Biophys Acta, 1999, 1450(3): 364-373.
[97] Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith SK. Determination of the transcript profile of human Endometrium. Mol Hum Reprod, 2003, 9(1): 19-33.
[98] Xu B, Lin L, Rote NS. Identification of a stress-induced protein during human trophoblast differentiation by differential display analysis. Biol Reprod, 1999, 61(3): 681-686.
[99] Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, TaylorRN, Lessey BA, Giudice LC. Global gene profiling in human endometrium during the window of implantation. Endocrinology, 2002, 143(6): 2119-38.
[100] Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith SK. Determination of the transcript profile of human endometrium, Mol Hum Reprod. 2003; 9(1): 19-33.
[101] Stein S, Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS 2nd,Wang M, Liang P. NDRG1 is necessary for p53-dependent apoptosis, J Biol Chem, 2004, 279(47): 48930-48940.
[102] Zhou D, Salnikow K, Costa M. Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res, 1998, 58(10): 2182-2189.
[103] Salnikow K, Blagosklonny MV, Ryan H, Johnson R, Costa M. Carcinogenic nickel induces genes involved with hypoxic stress, Cancer Res, 2000,60(1): 38-41.
[104] Zhao W, Tang R,HuangY,Wang W. Clong and expression pattern of the human NDRG3 gene. Biochem Biophys Acta, 2001, 1519(1-2): 134-138.
[105] Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics, 2001, 73(1): 86-97.
[106] Charles J. Sherr. Principles of Tumor Suppression. Cell, 2004, 116: 235-246.
[107] Winters ZE. P53 pathways involving G2 checkpoint regulators and the role of their subcellular localization. JR Coll Surg Edinb, 2002 ,47(4): 591-598.
[108] Ridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003, 22(56): 9030-9040.
[109] Ray JM, Stetler-Stevenson WG. TIMP-2 expression modulates human melanoma cell adhesion and motility. Ann N Y Acad Sci. 1994, 732: 233-247.
[110] Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89(17): 1260-1270.
[111] Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988, 80(3): 200-204.
[112] B Vennstrom, D Sheiness, J Zabielski, and J M Bishop. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol, 1982, 42(3): 773-779.
[113] Cole, M. D. The myc oncogene: its role in transformation and differentiation. Annu. Rev. Genet, 1986, 20: 361-384.
[114] Dalla-Favera, R., E. P. Gelmann, S. Martinotti, G. Franchini, T. S. Papas, R. C. Gallo, and F. Wong-Staal. Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc. Natl. Acad. Sci. USA, 1982, 79: 6497-6501.
[115] Dang, C. V. c-myc oncoprotein function. Biochim. Biophys. Acta, 1991, 1072:103-113.
[116] Facchini, L. M., and L. Z. Penn. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J, 1998, 12: 633-651.
[117] Henriksson, M., and B. Luscher. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res, 1996, 68: 109-182.
[118] Lemaitre, J. M., R. S. Buckle, and M. Mechali. c-Myc in the control of cell proliferation and embryonic development. Adv. Cancer Res, 1996, 70: 95-144.
[119] Spencer, C. A., and M. Groudine. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res, 1991, 56: 1-48.
[120] Hermeking, H., and D. Eick. Mediation of c-myc-induced apoptosis by p53. Science, 1994, 265: 2091-2093.
[121] Wagner, A. J., J. M. Kokontis, and N. Hay. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21wafl/cipl. Genes Dev, 1994, 8: 2817-2830.
[122] Gerard I. Evan, Karen H. Vousden. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411(17): 342-348.
[123] Davis, A. C., M. Wims, G. D. Spotts, S. R. Hann, and A. Bradley. A null c-Myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev, 1993,7:671-682.
[124]Charron J,Malynn BA,Fisher P,Stewart V,Jeannotte L,Goff SP,Robertson EJ,Alt FW.Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene.Genes Dev,1992,6(12A):2248-2257.
[125]Shimono A,Okuda T,Kondoh H.N-myc-dependent repression of ndrl,a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant.Mech Dev,1999,83(1-2):39-52.
[126]Okuda T,Kondoh H.Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc.Biochem Biophys Res Commun,1999,266(1):208-215.
[127]Yamauchi Y,Hongo S,Ohashi T,Shioda S,Zhou C,Nakai Y,Nishinaka N,Takahashi R,Takeda F,Takeda M.Molecular cloning and characterization of a novel developmentally regulated gene,Bdml,showing predominant expression in postnatal rat brain.Brain Res Mol Brain Res,1999,68(1-2):149-158.
[128]Nishinaka N,Hongo S,Zhou CJ,Shioda S,Takahashi R,Yamauchi Y,Ohashi T,Ohki T,Nakada N,Takeda F,Takeda M.Identification of the novel developmentally regulated gene,Bdm2,which is highly expressed in fetal rat brain.Brain Res Dev Brain Res,2000,120(1):57-64.
[129]张健.Myc调控人NDRG1和NDRG2的机制研究.第四军医大学博士论文,2006年6月.
[130]刘娜.DNA损伤中NDRG2与P53的关系及NDRG2在P53信号转导通路中的功能研究.第四军医大学博士论文,2007年6月.
[131]Dae-Young Kang,Kyung-Hee Kim,Jin-Man Kim,Seok-Hyung Kim,Ji-Young Kim,Haing-Woon Baik,Yong-Sung Kim.High Prevalence of RET,RAS,and ERK Expression in Hashimoto's Thyroiditis and in Papillary Thyroid Carcinoma in the Korean Population.THYROID,2007,17:1031-1038.
[132]Sinicrope FA,Ruan SB,Cleary KR,Stephens LC,Lee JJ,Levin B.bcl-2and p53 oncoprotein expression during colorectal tumorigenesis.Cancer Res,1995,55:237-241.
[133]Anders Lorentzen,Lotte K Vogel,Rikke H Lewinsky,Mona Saebo,Camilla F Skjelbred,Sine Godiksen,Geir Hoff,Kjell M Tveit,Inger Marie Bowitz Lothe,Tone Ikdahl,Elin H Kure,Cathy Mitchelmore.Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.BMC Cancer,2007,7:192-200.
[134]Okuda T,Kokame K,Miyata T.Differential expression patterns of NDRG family proteins in the central nervous system.J Histochem Cytochem,2008,56:175-82.
[2] Hundahl S A, Fleming ID, Fremgen AM, Menck HR. A National Cancer Date Base reort on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 1998, 83: 2638-2648.
[3] Ain,K.B. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaces. Thyroid, 1998, 8: 715-726.
[4] Stewart BW, Kleihues P. World Cancer Report, 2003, IARC Press: Lyon.
[5] Randolph GW. Follicular carcinoma of the thyroid. 2003, Saunders: Philadelphia.
[6] Negri E, Dal Maso L, Ron E, Lavecchia C, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F, Wingren G, Rosaria Galani M, Hardell L, Glattre E, Lund E, Levi F, Linos D, Braga C, Franceschi S. A pooled analysis of case-control studies of thyroid cancer. Ⅱ .Menstrual and reproductive factors. Cancer Causes Control, 1999, 10: 143-155.
[7] Tai P, Mould RF, Prysyazhnyuk Aye, Gristchenko VG, Obodovsky IA. Descriptive epidemiology of thyroid caicinoma. Current Oncology, 2003, 10: 54-65.
[8] Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer, 2002, 2: 543-549.
[9] Williams ED, Doniach I, Bjarnason O, MichieW. Thyriod cancer in an iodide rich area: a histopathological study. Cancer, 1977, 39: 215-222.
[10] Cooper DS, Axelrod L, DeGroot LJ, Vickery ALJr, Maloof F. Congenital goiter and the development of metastatic follicular carcinoma with evidence for a leak of nonhormonal iodide: clinical, pathological, kinetic, and biochemical studies and a review of the literature. J Clin Endocrinol Metab, 1981, 52: 294-306.
[11] Ruben Harach H. Familial nonmedullary thyroid neoplasia. Endocr Pathol, 2001, 12:97-112.
[12] Harach HR, Escalante DA, Day ES.Thyroid cancer and thyroiditis in salta, Argentina: a 40-yr study in relation to iodine prophylaxis.Endocr Pathol, 2002, 13: 175-181.
[13] Tamimi DM. The association between chronic lymphocytic thyrioditis and thyroid tumors. Int J Surg Pathol, 2002, 10: 141-146.
[14] Takahashi MH, Thomas GA, Williams ED. Evidence for mutual interdependence of epithelium and stromal lymphoid cells in a subset of papillary carcinomas. Br J Cancer, 1995, 72: 813-817.
[15] Schaffler A, Palitzsch KD, Seiffarth C, Riedhammer FJ Hofstaedter F. Coexisting thyroiditis is associatd with lower tumor stage in thyroid carcinoma. Eur J Clin Invest, 1998,28: 838-844.
[16] Toti P, Tanganelli P, Schurfelld K, Stumpo M, Barbagli L, Luzi P. Scarring in papillary carcinoma of the thyroid: report of two new cases with exuberant nodular fasciitis-He stroma. Histopathology, 1999, 35: 418-422.
[17] Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer, 2003, 103: 105-109.
[18] Kuratomi Y, Kumamoto Y, Sakai Y, Komiyama S. Carotid body tumor associated with differentiated thyroid carcinoma. Eur Arch Otorhinolaryngol 251 Suppl, 1994, 1: S91-S94.
[19] Gardner EJ. A genetic and clinical study of intertinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet, 1991, 167-176.
[20] Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet: 1953, 5: 139-148.
[21] Houlston RS. Genetic predisposition to non-medullary thyroid cancer. Nucl Med Commun, 1998, 19: 911-913.
[22] Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. Mod Pathol , 1999, 12:400-411.
[23] Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S. Germline mutation of the APC gene in paytients with familial adenomatous polyposisi-associated thyroid carcinoma: result from a uropean cooperative study. J Clin Endocrinol Metab, 2000, 85: 286-292.
[24] Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. PTEN is essential for embryonic development and tumor suppression. Nat Genet , 1998, 19: 348-355.
[25] Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res , 2003, 63: 1454-1457.
[26] Soares P, Trovisco V, Rocha AS,Lima J, Castro P, Preto A, Maximo V,Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC tearrangements are ailernative events in the etiopathogenesis of papillary thyroid carcinoma. Oncogene, 2003, 22: 4578-4580.
[27] Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE. Ras point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab, 2003, 88: 2318-2326.
[28] Pisarchik AV, Ermak G, Fomicheva V, Kartel NA, Figge J. The ret/ PTC 1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. Thyroid, 1998, 8: 133-139.
[29] Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by RET/ PTC 1 oncogene in thyroid-targeted transgenic mice. Oncogene , 1999, 18: 3659-3665.
[30] Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D. Papillary thyroid carcinoma oncogene(RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol, 1998, 153: 1443-1450.
[31] Nikiforova MN, Kimnra ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. BRAF mutation in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 2003, 88: 5399-5404.
[32] Oyama T, Ichimura E, Sano T. C-met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Int, 1998, 48:763-768.
[33] Ruco LP, Ranalli T, Marzullo A, Biano P, Prat M, Comoglio PM, Baroni CD. Expression of Met protein in thyroid tumors. J Pathol, 1996, 180: 266-270.
[34] Komoike Y, Tamaki Y, Sakita I. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma. Int J Oncol, 1999, 14: 1157-1162.
[35] Schulte KM, Staudt S, Niederracher D. Rare loss of heterozygosity of the MTS 1 and MTS 2 tumor suppressor genes in differentiated human thyroid cancer. Horm Metab Res, 1998, 30: 549-554.
[36] Yamashita H, Noduchi S. Thyroid cancer associated with adenomatous goiter: An analysis of the incidence and clinical factors. Jap J Surg , 1997, 27: 495-499.
[37] Grunwald F, Kaelicke T. Fluorine-fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study. Eur J Nucl Med, 1999,26: 1547-1552.
[38] Bennedbaek FN, Hegedus L. Management of the solitary thyroid nodule: a retrospective analysis of eighty cases. Thyroid, 2000, 8: 1039-1044.
[39] Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med, 1993, 13: 699-709.
[40] Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky , Haugen BR, Sherman SL, Cooper DS, Braunstein GD, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for lowrisk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 2003, 88: 1433-1441.
[41] Elisei R, Bottici V, LuchettiF, Di Coscio G, Romei C, Grasso L. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab, 2004, 89: 163-168.
[42] Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature , 1996, 379: 458-460.
[43] Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM. Cloning of the human sodium iodide smporter. Biochem Biophys Res Commun , 1996, 226: 339-345.
[44] Schmutzler C, Winzer R, Meissner-Weigl. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun, 1997, 240: 832-838.
[45] Woolner LB, Lemmon ML, Beahrs OH, Black BM, McConahey WM, Keating FR. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J Clin Endocrinol Metab, 1960, 20:89-105.
[46] Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the U.S.,1985-1995. Cancer , 1998, 82: 2638-2648.
[47] Shaha AR. The National Cancer Date Base report on thyroid carcinoma.Reflections of practice patterns. Cancer, 1998, 83: 2434-2436.
[48] Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a populatin-based study of 15,698 cases for the Surveillance, Epidemiology and End Results(SEER) Program 1973-1991. Cancer , 1997, 79: 564-573.
[49] Ando H, Funahashi H, Ito M, Imai T, Takagi H. Proliferating cell nuclear antigen expression in papillary thyroid carcinoma. J Clin Pathol, 1996, 49: 657-659.
[50] Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. Downregulation of p27klpl and Ki67/Mibl labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol, 1999, 23: 678-685.
[51]Aust G,Eichler W,Laue S,Lehmann I,Heldin NE,Lotz O,Scherbaum WA,Dralle H,Hoang Vu C.Cd97:a differentiation marcker in human thyroid caicinomas.Cancer Res,1997,57:1798-1806.
[52]Walgenbach S,Sternheirn E,Bittinger F,Gorges R,Andreas J,Junginger T.Prognostic value of e-cadherin in papillary thyroid carcinoma.Chirurg,1998,69:186-190.
[53]Fontanini G,Vignati S,Pacini F,Pollina L,Basolo F.Microvessel count:an indicator of poor outcome in medullary thyroid caicinoma but not in other types of thyroid caicinoma.Mod Patho,1996,19:636-641.
[54]Wong NA,Willott J,Kendall MJ,Sheffield EA.Mesurement of vascularity as a diagnostic and prognostic tool for well differentiated thyroid tumors'comparison of different methods of assessing vascularity.J Clin Pathol,1999,52:593-597.
[55]邓艳春,药立波,刘新平,等.人脑内ACP样结构域新基因的发现.生物化学与生物物理进展,2001;28(1):72-76.
[56]Nagase T,Ishikawa K,Suyama M,Kikuno R,Hirosawa M,Miyajima N,Tanaka A,Kotani H,Nomura N,Ohara O,Prediction of the coding sequences of unidentified human genes.ⅩⅢ.The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro,DNA Res,1999;6(1):63-70.
[57]李剑,刘新平,林树新,等.一种新的抑癌候选基因—NDRG2在人类正常组织及相应肿瘤组织中的表达.生物化学与生物物理进展,2002;29(1):223-227.
[58]Qu X,Zhai Y,Wei H,Zhang C,Xing G,Yu Y,He F.Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family,Mol Cell Biochem,2002;229(1-2):35-44.
[59]王立峰.应激刺激对NDRG2蛋白在细胞内定位的影响.第四军医大学硕士论文,2003年P79-81.
[60]Jing Zhang,Junye Liu,Xia Li,Fuyang Li,Lifeng Wang,Jian Zhang,Xinping Liu,Lan Shen,Na Liu,Yanchun Deng,Angang Yang,Hua Han,Mujun Zhao,Libo Yao.The physical and functional interaction of NDRG2with MSP58 in cells.Biochemical and Biophysical Research Communications,2007;352:6-11.
[61]Kaelin WG Jr.Functions of the retinoblastoma protein,Bioessays.1999;21:950-958.
[62]Tong D,Kucera E,Schuster E,Schmutzler RK,Swoboda H,Reinthaller A,Leodolter S,Zeillinger R.Loss of heterozygosity(LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors,Int J Cancer,2000;88:319-322
[63]Manel Esteller,CpG island hypermethylation and tumor suppressor genes:a booming present,a brighter future,Oncogene,2002;21:5427-5440.
[64]Pamela M.Pollock,Mitchell S.Stark,Jane M.Palmer.Mutation Analysis of the CDKN2A Promoter in Australian Melanoma Families,Genes,Chromosomes & Cancer.2001,32:89-94.
[65]Deng Y,Yao L,Chau L,Ng SS,Peng Y,Liu X,Au WS,Wang J,Li F,Ji S,Han H,Nie X,Li Q,Kung HF,Leung SY,Lin MC,N-Myc downstream-regulated gene 2(NDRG2) inhibits glioblastoma cell proliferation,Int J Cancer,2003,106(3):342-347.
[66]刘娜,刘新平,王立峰,张健,王晓斌,药立波.抑癌侯选基因NDRG2在乳腺肿瘤组织及乳腺癌细胞系中的表达分析.第四军医大学学报,2004;25(12):1065-1068.
[67]Hu XL,Liu XP,Lin SX,Deng YC,Liu N,Li X,Yao LB.NDRG2 expression and mutation in human liver and pancreatic cancers, World J Gastroenterol, 2004, 10(23):3518-3521.
[68] Reetta (A|¨)ss(a|¨)m(a|¨)ki, Maarit Sarlomo-Rikala, Jose Antonio Lopez-Guerrero, Jerzy Lasota 3,Leif C. Andersson, Antonio Llombart-Bosch, Markku Miettinen, Sakari Knuutila .Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors, Genes Chromosomes Cancer, 2007, 46(6): 564-567.
[69] Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G,Gutmann DH, Perry A, Integrative genomic analysis identifies NDRG2 as a candidatetumor suppressor gene frequently inactivated in clinically aggressive meningioma, Cancer Res, 2005, 65: 7121-7126.
[70] Wu GQ, Liu XP, Wang LF, Zhang WH, Zhang J, Li KZ, Dou KF, Zhang XF, Yao LB. Induction of apoptosis of HepG2 cells by NDRG2, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2003, 19(4): 357-360.
[71] Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S, Yang A, Han H, Zhang Y, Zhang J, Han W, Liu X. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells.Cell Physiol Biochem. 2008, 21(1-3): 239-250.
[72] Hu XL, Liu XP, Deng YC, Lin SX, Wu L, Zhang J, Wang LF, Wang XB, Li X, Shen L, Zhang YQ, Yao LB. Expression analysis of the NDRG2 gene in mouse embryonic and adult tissues. Cell Tissue Res, 2006, 325(1): 67-76.
[73] Zhang J, Wang JC, Han YH, Wang LF, Ji SP, Liu SX, Liu XP, Yao LB. High expression of bcl-x(L) in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol, 2005, 113(4): 247-254.
[74] Jian Zhang, Fuyang Li, Xinping Liu, Lan Shen, Junye Liu, Jin Su, and Libo Yao. The repression of human differentiation related gene NDRG2 expression by MYC via MIZ 1 dependent interaction with the NDRG2 core promoter. J Biol Chem, 2006, 281(51) : 39159-39168.
[75] Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK, Chang YS, Paik SG,Lim JS. Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells, FEBS Lett, 2003; 553(3): 413-418.
[76] James T. Murray, David G. Campbell, Nicholas Morrice, Gillian C. Auld, Natalia Shpiro, Rodolpho Marquez, Mark Peggie, Jenny Bain, Graham B. Bloomberg, Florian Grahammer. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3 . Biochem, 2004, 384: 477-488.
[77] Lang F, Cohen P. Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. Science STKE, 2001, 108: 17.
[78] Firestone G.L, Giampaolo J.R, O'Keeffe B.A. Stimulus-dependent regulation of serum and glucocorticoid-induced protein kinase (SGK) transcription, sub-cellular location and enzymatic activity. Cell. Physiol. Biochem, 2003; 13: 1-12.
[79] Mitchelmore C, Buchmann-Moller S, Rask L, West MJ, Troncoso JC, Jensen NA. NDRG2: a novel Alzheimer's disease associated protein. Neurobiol Dis, 2004 ; 16(1): 48-58.
[80] Takahashi K, Yamada M, Ohata H, Momose K, Higuchi T, Honda K, Yamada M. Expression of Ndrg2 in the rat frontal cortex after antidepressant and electroconvulsive treatment. Int J Neuropsychopharmacol, 2005, 8(3): 381-389.
[81] Kou Takahashi, Misa Yamada, Hisayuki Ohata, Kazuo Hond, Mitsuhiko Yamad. Ndrg2 promotes neurite outgrowth of NGF-differentiated PC12 cells . Neuroscience Letters, 2005, 388 : 157-162.
[82] James G. Burchfield, Alecia J. Lennard, Sakura Narasimhan, William E. Hughes,Valerie C. Wasinger, Garry L. Corthals, Tomohiko Okuda, Hisato Kondoh,Trevor J. Biden, and Carsten Schmitz-Peiffer. Akt Mediates Insulin-stimulated Phosphorylation of Ndrg2. The Journal Of Biological Chemistry, 2004, 279(18) : 18623-18632.
[83] Sheerazed Boulkroun, Michel Fay, Maria-Christina Zennaro, Brigitte Escoubet, Frederic Jaisser, Marcel Blot-Chabaud, Nicolette Farman, Nathalie Courtois-Coutry. Characterization of Rat NDRG2 (N-Myc Downstream RegulatedGene 2), a Novel Early Mineralocorticoid-specific Induced Gene. The Journal Of Biological Chemistry, 2002, 277(35): 31506-31515.
[84] Sheerazed Boulkroun, Cathi Le Moellic,Marcel Blot-Chabaud, Nicolette Farman Nathalie Courtois-Coutry. Expression of androgen receptor and androgen regulation of NDRG2 in the rat renal collecting duct. Arch Eur J Physiol, 2005, 451: 388-394.
[85] Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis GRP78/BiP and novel genes. J Biol Chem, 1996, 271(47): 29659-65.
[86] van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in Colorectal neoplasms. Lab Invest, 1997, 77(1): 85-92.
[87] Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem, 2002, 229(1-2): 35-44. [88] Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics. 2001,73: 86-97.
[89] Lachat P, Shaw P, Gebhard S, Van Belzen N, Chaubert P, Bosman FT. Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol, 2002, 118(5): 399-408.
[90] Kalaydjieva L, Hallmayer J, Chandler D, Savov A, Nikolova A, Angelicheva D, King R. H, Ishpekova B. Gene mapping in Gypsies identifies a nove demyelinating neuropathy on chromosome 8q24. Nature Genet, 1996, 14: 214-217.
[91] van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in Colorectal neoplasms. Lab Invest, 1997, 77(1): 85-92.
[92] Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert P, Bosman FT. Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol, 2002, 118(5): 399-408.
[93] Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res, 1998; 58(19): 4439-4444.
[94] Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation related, putative metastatic suppressor gene in human colon cancer. Cancer Res, 2000, 60(3): 749-755.
[95] Plonczynski M, Hardy CL, Safaya S, Harrell A, McCoy L, Brinson A, Agwarangbo L, Steinberg MH. Induction of globin synthesis in K562 cells is associated with differential expression of transcription factor genes. Blood Cells Mol Dis, 1999,25(3-4): 156-165.
[96] Piquemal D, Joulia D, Balaguer P, Basset A, Marti J, Commes T. Differential expression of the RTP/Drgl/Ndrl gene product in Proliferating and growth arrested cells. Biochim Biophys Acta, 1999, 1450(3): 364-373.
[97] Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith SK. Determination of the transcript profile of human Endometrium. Mol Hum Reprod, 2003, 9(1): 19-33.
[98] Xu B, Lin L, Rote NS. Identification of a stress-induced protein during human trophoblast differentiation by differential display analysis. Biol Reprod, 1999, 61(3): 681-686.
[99] Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, TaylorRN, Lessey BA, Giudice LC. Global gene profiling in human endometrium during the window of implantation. Endocrinology, 2002, 143(6): 2119-38.
[100] Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith SK. Determination of the transcript profile of human endometrium, Mol Hum Reprod. 2003; 9(1): 19-33.
[101] Stein S, Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS 2nd,Wang M, Liang P. NDRG1 is necessary for p53-dependent apoptosis, J Biol Chem, 2004, 279(47): 48930-48940.
[102] Zhou D, Salnikow K, Costa M. Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res, 1998, 58(10): 2182-2189.
[103] Salnikow K, Blagosklonny MV, Ryan H, Johnson R, Costa M. Carcinogenic nickel induces genes involved with hypoxic stress, Cancer Res, 2000,60(1): 38-41.
[104] Zhao W, Tang R,HuangY,Wang W. Clong and expression pattern of the human NDRG3 gene. Biochem Biophys Acta, 2001, 1519(1-2): 134-138.
[105] Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics, 2001, 73(1): 86-97.
[106] Charles J. Sherr. Principles of Tumor Suppression. Cell, 2004, 116: 235-246.
[107] Winters ZE. P53 pathways involving G2 checkpoint regulators and the role of their subcellular localization. JR Coll Surg Edinb, 2002 ,47(4): 591-598.
[108] Ridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003, 22(56): 9030-9040.
[109] Ray JM, Stetler-Stevenson WG. TIMP-2 expression modulates human melanoma cell adhesion and motility. Ann N Y Acad Sci. 1994, 732: 233-247.
[110] Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89(17): 1260-1270.
[111] Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988, 80(3): 200-204.
[112] B Vennstrom, D Sheiness, J Zabielski, and J M Bishop. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol, 1982, 42(3): 773-779.
[113] Cole, M. D. The myc oncogene: its role in transformation and differentiation. Annu. Rev. Genet, 1986, 20: 361-384.
[114] Dalla-Favera, R., E. P. Gelmann, S. Martinotti, G. Franchini, T. S. Papas, R. C. Gallo, and F. Wong-Staal. Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc. Natl. Acad. Sci. USA, 1982, 79: 6497-6501.
[115] Dang, C. V. c-myc oncoprotein function. Biochim. Biophys. Acta, 1991, 1072:103-113.
[116] Facchini, L. M., and L. Z. Penn. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J, 1998, 12: 633-651.
[117] Henriksson, M., and B. Luscher. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res, 1996, 68: 109-182.
[118] Lemaitre, J. M., R. S. Buckle, and M. Mechali. c-Myc in the control of cell proliferation and embryonic development. Adv. Cancer Res, 1996, 70: 95-144.
[119] Spencer, C. A., and M. Groudine. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res, 1991, 56: 1-48.
[120] Hermeking, H., and D. Eick. Mediation of c-myc-induced apoptosis by p53. Science, 1994, 265: 2091-2093.
[121] Wagner, A. J., J. M. Kokontis, and N. Hay. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21wafl/cipl. Genes Dev, 1994, 8: 2817-2830.
[122] Gerard I. Evan, Karen H. Vousden. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411(17): 342-348.
[123] Davis, A. C., M. Wims, G. D. Spotts, S. R. Hann, and A. Bradley. A null c-Myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev, 1993,7:671-682.
[124]Charron J,Malynn BA,Fisher P,Stewart V,Jeannotte L,Goff SP,Robertson EJ,Alt FW.Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene.Genes Dev,1992,6(12A):2248-2257.
[125]Shimono A,Okuda T,Kondoh H.N-myc-dependent repression of ndrl,a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant.Mech Dev,1999,83(1-2):39-52.
[126]Okuda T,Kondoh H.Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc.Biochem Biophys Res Commun,1999,266(1):208-215.
[127]Yamauchi Y,Hongo S,Ohashi T,Shioda S,Zhou C,Nakai Y,Nishinaka N,Takahashi R,Takeda F,Takeda M.Molecular cloning and characterization of a novel developmentally regulated gene,Bdml,showing predominant expression in postnatal rat brain.Brain Res Mol Brain Res,1999,68(1-2):149-158.
[128]Nishinaka N,Hongo S,Zhou CJ,Shioda S,Takahashi R,Yamauchi Y,Ohashi T,Ohki T,Nakada N,Takeda F,Takeda M.Identification of the novel developmentally regulated gene,Bdm2,which is highly expressed in fetal rat brain.Brain Res Dev Brain Res,2000,120(1):57-64.
[129]张健.Myc调控人NDRG1和NDRG2的机制研究.第四军医大学博士论文,2006年6月.
[130]刘娜.DNA损伤中NDRG2与P53的关系及NDRG2在P53信号转导通路中的功能研究.第四军医大学博士论文,2007年6月.
[131]Dae-Young Kang,Kyung-Hee Kim,Jin-Man Kim,Seok-Hyung Kim,Ji-Young Kim,Haing-Woon Baik,Yong-Sung Kim.High Prevalence of RET,RAS,and ERK Expression in Hashimoto's Thyroiditis and in Papillary Thyroid Carcinoma in the Korean Population.THYROID,2007,17:1031-1038.
[132]Sinicrope FA,Ruan SB,Cleary KR,Stephens LC,Lee JJ,Levin B.bcl-2and p53 oncoprotein expression during colorectal tumorigenesis.Cancer Res,1995,55:237-241.
[133]Anders Lorentzen,Lotte K Vogel,Rikke H Lewinsky,Mona Saebo,Camilla F Skjelbred,Sine Godiksen,Geir Hoff,Kjell M Tveit,Inger Marie Bowitz Lothe,Tone Ikdahl,Elin H Kure,Cathy Mitchelmore.Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.BMC Cancer,2007,7:192-200.
[134]Okuda T,Kokame K,Miyata T.Differential expression patterns of NDRG family proteins in the central nervous system.J Histochem Cytochem,2008,56:175-82.